We demonstrated the relative expression level of leptin and leptin receptor in a pan-cancer panel, and revealed the dramatic upregulation of the leptin-leptin receptor axis in breast cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer, suggesting the potential critical role of this signaling node in tumor progression. Here, LEP is linked to lung carcinoma.